NeuroPace, Inc. (NPCE)
Price:
10.79 USD
( - -0.34 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Establishment Labs Holdings Inc.
VALUE SCORE:
3
2nd position
UFP Technologies, Inc.
VALUE SCORE:
10
The best
Viemed Healthcare, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NEWS
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-12 21:50:30NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
zacks.com
2025-08-12 18:26:04NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
globenewswire.com
2025-08-12 16:05:00-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
globenewswire.com
2025-08-01 07:30:00MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-07-02 10:00:00NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-06-27 10:00:00NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NeuroPace Announces Strategic CFO Transition
globenewswire.com
2025-06-24 16:05:00Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif.
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
prnewswire.com
2025-06-24 03:42:00LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ: NPCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
globenewswire.com
2025-06-23 12:49:00NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
businesswire.com
2025-06-22 12:36:00LOS ANGELES--(BUSINESS WIRE)---- $NPCE--NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-06-22 10:00:00NEW YORK , June 22, 2025 /PRNewswire/ -- APomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
accessnewswire.com
2025-06-16 14:55:00NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
accessnewswire.com
2025-06-13 10:15:00NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
accessnewswire.com
2025-06-13 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
accessnewswire.com
2025-06-12 10:30:00NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
No data to display
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-12 21:50:30NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
zacks.com
2025-08-12 18:26:04NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
globenewswire.com
2025-08-12 16:05:00-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
globenewswire.com
2025-08-01 07:30:00MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-07-02 10:00:00NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-06-27 10:00:00NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NeuroPace Announces Strategic CFO Transition
globenewswire.com
2025-06-24 16:05:00Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif.
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
prnewswire.com
2025-06-24 03:42:00LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ: NPCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
globenewswire.com
2025-06-23 12:49:00NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
businesswire.com
2025-06-22 12:36:00LOS ANGELES--(BUSINESS WIRE)---- $NPCE--NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
prnewswire.com
2025-06-22 10:00:00NEW YORK , June 22, 2025 /PRNewswire/ -- APomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
accessnewswire.com
2025-06-16 14:55:00NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
accessnewswire.com
2025-06-13 10:15:00NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
accessnewswire.com
2025-06-13 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
accessnewswire.com
2025-06-12 10:30:00NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).